How An Optimized Purification Platform Can Speed mAbs Clinical Production
Source: MilliporeSigma
Getting your antibody to clinical trials faster while being able to build a robust, scalable, and high-yielding process is a challenge many biotech companies face. By outsourcing to a CTDMO, you can benefit from an optimized platform process.
In this webinar, we showcase our purification development platform, including an MMC* chromatography step and how it allowed our client, Igyxos Biotherapeutics, to simplify and accelerate their clinical trial supply while achieving high-quality material.
*mixed-mode chromatography
Learn how a process platform can help:
- Accelerate your development journey
- Facilitate transfer and scale-up to production
- Gain knowledge on the molecule
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more